ArriVent BioPharma, Inc. SEC filings AVBP
ArriVent BioPharma, Inc. has 160 filings in SEC EDGAR's recent list, going back to Jun 23, 2021. Its latest annual report, Form ARS, was filed on Apr 28, 2026 for the period ended Dec 31, 2025. The latest quarterly report (Form 10-Q) was filed on Aug 12, 2026, covering the quarter ended Jun 30, 2026. The most recent current report (Form 8-K) was filed on Oct 26, 2026 (regulation fd disclosure, other events). The company's fiscal year ends on December 31.
| Form | Description | Filed | Period |
|---|---|---|---|
| 8-K |
Current report
Regulation FD disclosure, Other events
|
Oct 26, 2026 | Oct 25, 2026 |
| 8-K |
Current report
Regulation FD disclosure
|
Oct 19, 2026 | Oct 19, 2026 |
| 8-K |
Current report
Regulation FD disclosure, Other events
|
Oct 13, 2026 | Oct 12, 2026 |
| 8-K |
Current report
Regulation FD disclosure, Other events
|
Oct 6, 2026 | Oct 6, 2026 |
| 8-K |
Current report
Material agreement, Results of operations
|
Aug 12, 2026 | Aug 11, 2026 |
| 8-K |
Current report
Shareholder vote results
|
Jun 22, 2026 | Jun 18, 2026 |
| 8-K |
Current report
Other events
|
May 11, 2026 | May 11, 2026 |
| 8-K |
Current report
Results of operations
|
May 11, 2026 | May 11, 2026 |
| 8-K |
Current report
Regulation FD disclosure, Other events
|
Mar 17, 2026 | Mar 17, 2026 |
| 8-K |
Current report
Results of operations
|
Mar 5, 2026 | Mar 5, 2026 |
| 8-K |
Current report
Results of operations
|
Nov 10, 2025 | Nov 10, 2025 |
| 8-K |
Current report
Regulation FD disclosure, Other events
|
Sep 9, 2025 | Sep 9, 2025 |
| 8-K |
Current report
Results of operations
|
Aug 11, 2025 | Aug 11, 2025 |
| 8-K |
Current report
Other events
|
Jul 21, 2025 | Jul 21, 2025 |
| 8-K |
Current report
Material agreement, Other events
|
Jul 2, 2025 | Jul 1, 2025 |
| 8-K |
Current report
Regulation FD disclosure, Other events
|
Jun 23, 2025 | Jun 23, 2025 |
| 8-K |
Current report
Shareholder vote results
|
Jun 20, 2025 | Jun 18, 2025 |
| 8-K |
Current report
Results of operations
|
May 12, 2025 | May 12, 2025 |
| 8-K |
Current report
Officer or director change, Regulation FD disclosure
|
Apr 28, 2025 | Apr 23, 2025 |
| 8-K |
Current report
Auditor change
|
Mar 13, 2025 | Mar 11, 2025 |
| 8-K |
Current report
Results of operations
|
Mar 3, 2025 | Mar 3, 2025 |
| 8-K |
Current report
Material agreement, Regulation FD disclosure
|
Jan 22, 2025 | Jan 21, 2025 |
| 8-K |
Current report
Results of operations
|
Nov 14, 2024 | Nov 14, 2024 |
| 8-K |
Current report
Regulation FD disclosure, Other events
|
Sep 9, 2024 | Sep 9, 2024 |
| 8-K |
Current report
Results of operations
|
Aug 14, 2024 | Aug 14, 2024 |
| 8-K/A |
Amended current report
Officer or director change
|
Jul 9, 2024 | May 16, 2024 |
| 8-K/A |
Amended current report
Officer or director change
|
Jul 9, 2024 | Apr 20, 2024 |
| 8-K |
Current report
Material agreement, Regulation FD disclosure
|
Jun 5, 2024 | Jun 4, 2024 |
| 8-K |
Current report
Officer or director change
|
May 16, 2024 | May 16, 2024 |
| 8-K |
Current report
Results of operations
|
May 8, 2024 | May 8, 2024 |
| 8-K |
Current report
Officer or director change
|
Apr 22, 2024 | Apr 20, 2024 |
| 8-K |
Current report
Results of operations
|
Mar 28, 2024 | Mar 28, 2024 |
| 8-K |
Current report
Bylaw or fiscal year change, Other events
|
Jan 30, 2024 | Jan 30, 2024 |
Showing 33 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.
New to this? Read What Are SEC Filings? 10-K, 10-Q, 8-K and Other Forms Explained.
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- AVBP (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Newtown Square, PA
- SEC filer status
- , Emerging growth company
- SEC CIK
- 1868279
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Source: SEC EDGAR filings. This is company-reported data, not investment advice.